close Icon

Research Articles

Explore our library of peer-reviewed publications below, with contributions from Burnet researchers.

See also: Research Reports + Policy Briefs

Form Loading Icon
Kazakhstan can achieve ambitious HIV targets despite expected donor withdrawal by combining improved ART procurement mechanisms with allocative and implementation efficiencies.

Shattock AJ, Benedikt C, Bokazhanova A, Đurić P, Petrenko I, Ganina L, Kelly SL, Stuart RM, Kerr CC, Vinichenko T, Zhang S, Hamelmann C, Manova M, Masaki E, Wilson DP, Gray RT

Kazakhstan can achieve ambitious HIV targets despite expected donor withdrawal by combining improved ART procurement mechanisms with allocative and implementation efficiencies.
Dropout in clinical trials of pharmacological treatment for methamphetamine dependence: the role of initial abstinence.

Cook R, Quinn B, Heinzerling K, Shoptaw S

Dropout in clinical trials of pharmacological treatment for methamphetamine dependence: the role of initial abstinence.
The Bacterial Peptidoglycan-Sensing Molecules NOD1 and NOD2 Promote CD8<sup>+</sup> Thymocyte Selection.

Martinic MM, Caminschi I, O'Keeffe M, Thinnes TC, Grumont R, Gerondakis S, McKay DB, Nemazee D, Gavin AL

The Bacterial Peptidoglycan-Sensing Molecules NOD1 and NOD2 Promote CD8<sup>+</sup> Thymocyte Selection.
An optimized hepatitis C virus E2 glycoprotein core adopts a functional homodimer that efficiently blocks virus entry.

McCaffrey K, Boo I, Owczarek CM, Hardy MP, Perugini MA, Fabri L, Scotney P, Poumbourios P, Drummer HE

Hepatitis C An optimized hepatitis C virus E2 glycoprotein core adopts a functional homodimer that efficiently blocks virus entry.
The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigs.

Vietheer PT, Boo I, Gu J, McCaffrey K, Edwards S, Owczarek C, Hardy MP, Fabri L, Center RJ, Poumbourios P, Drummer HE

The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigs.
Differentiating founder and chronic HIV envelope sequences.

Murray JM, Maher S, Mota T, Suzuki K, Kelleher AD, Center RJ, Purcell D

Differentiating founder and chronic HIV envelope sequences.